



NEWS RELEASE

For Immediate Release: Monday, April 30, 2007

Contact: Howard Root, CEO
James Hennen, CFO
Vascular Solutions, Inc.
(763) 656-4300

VASCULAR SOLUTIONS ANNOUNCES INITIAL SALES OF THROMBI-PAD™ 3X3 HEMOSTAT TO KING PHARMACEUTICALS

MINNEAPOLIS, Minnesota, April 30, 2007 -- Vascular Solutions, Inc. (Nasdaq:VASC) announced today that, pursuant to a series of agreements entered into by Vascular Solutions and King Pharmaceuticals, Inc. in January 2007, Vascular Solutions has provided King with initial launch quantities of the Thrombi-Pad 3x3 hemostatic pad for the control of moderate to severe bleeding. King's hospital field sales force will promote the product for use in trauma and emergency medical settings. Vascular Solutions expects to receive a \$1 million milestone payment from King resulting from the first sale of Thrombi-Pad by King to end-users during May.

As previously disclosed, Vascular Solutions granted King an exclusive license to its hemostat products for use outside of catheterization and electrophysiology laboratories, which includes the Thrombi-Pad hemostat. The license also includes Vascular Solutions' Thrombi-Gel® hemostat and Thrombi-Paste™ hemostat, which is currently in development. Each of these products includes King's Thrombin-JMI® (thrombin, topical, bovine, USP) as a component. Vascular Solutions will exclusively manufacture and supply these products to King under a long term manufacturing agreement.

Howard Root, Chief Executive Officer of Vascular Solutions, Inc. commented, "The transaction with King Pharmaceuticals regarding our hemostat products is proceeding according to plan. At the launch meeting held with King's 100+ person hospital field sales force in March, I was particularly impressed with the energy and focus of King's organization to launch the newly re-branded Thrombi-Pad 3x3 hemostat into the trauma and emergency department markets. We believe that King's focus and energy provides an excellent strategy to introduce the Thrombi-Pad into the substantial market opportunity for active hemostats in trauma settings."

King's license to Thrombi-Pad and the Thrombi-Gel hemostats covers all market opportunities other than the catheterization and electrophysiology labs where Vascular Solutions currently promotes its hemostatic products through Vascular Solutions' direct sales force.

About Thrombi-Pad™

Thrombi-Pad (formerly branded as the Thrombix® and the D-Stat Dry™ 3x3 hemostats) is a powerful hemostatic dressing with a simple "open and apply" solution for temporary control of moderate to severe bleeding. Thrombi-Pad utilizes Thrombin-JMI in a bandage configuration designed for application in trauma and emergency medical settings.

About Thrombi-Gel®

Thrombi-Gel is a pre-mixed and shelf-stable foam pad of gelatin and Thrombin-JMI that is applied topically for the control of bleeding. Thrombi-Gel is available in three sizes – 10, 40 and 100 – to meet physician preferences, with an additional Thrombi-Paste version under development.

About Vascular Solutions

Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within interventional radiology and interventional cardiology. The company's five main product categories consist of hemostat (blood clotting) products, extraction catheters, vein products, specialty catheters and access products. New products introduced since the second half of 2003 include the Vari-Lase® endovenous laser product line for the treatment of varicose veins, the D-Stat Dry™ hemostatic bandage for the rapid control of topical bleeding, the Pronto™ extraction catheter for the aspiration of soft thrombus, the Langston® dual lumen specialty catheter for the measurement of aortic stenosis and the Twin-Pass® dual access specialty catheter for dual wire access in interventional procedures.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2006 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of profitability, exposure to intellectual property claims, dependence on key vendors, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to www.vascularsolutions.com.

###